Sacituzumab Govitecan

Antibody–drug conjugate

Approvedregulatory verdict

Evidence outlook

Approved: HR+/HER2- Metastatic Breast Cancer, Breast Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Non-Small Cell Lung Cancer · Phase 3Endometrial Cancer · Phase 3Urothelial Carcinoma · Phase 3

Also approved (8)
US
  • Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line TRODELVY as a single agent is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor based therapy. TRODELVY, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 [Combined Positive Score (CPS ≥ 10)] as determined by
  • Locally Advanced or Metastatic HR-positive, HER2-negative Breast Cancer TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
Product first approved 2020FDA label
EU
  • Trodelvy as monotherapy for adults with unresectable or metastatic triple-negative breast cancer who have not received prior systemic therapy for metastatic disease and are not candidates for PD-(L)1 inhibitorsgilead.com
  • Monotherapy for unresectable or metastatic HR-positive, HER2-negative breast cancer after endocrine-based therapy and at least two further systemic therapiesgilead.com
  • Trodelvy: unresectable or metastatic triple-negative breast cancer after at least two prior therapies (initial authorisation)EMA
Product first approved 2021
JP
  • Treatment of hormone receptor-negative and human epidermal growth factor receptor 2 (HER2)-negative unresectable or recurrent breast cancer in patients who have previously been treated with chemotherapy
Product first approved 2024PMDA
CN
  • Unresectable locally advanced or metastatic triple-negative breast cancer after at least two prior systemic therapies (Everest Medicines)
Product first approved 2022biospace.com
CA
  • TRODELVY (sacituzumab govitecan) is indicated for: • the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior therapies, at least one of them for metastatic disease. • the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
Product first approved 2021Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (18)
Breast Cancer
NCT07178730 · Women's Cancer Study Group GmbH
2026-08-30 – 2033-03-31 · Breast Cancer, Triple-negative Breast Cancer
What this study did
NCT06081244 · Women's Cancer Study Group GmbH
2024-10-10 – 2029-09 · Triple Negative Breast Cancer
What this study did
NCT05552001 · UNICANCER
2023-10-05 – 2028-05-06 · Triple Negative Breast Cancer, Metastatic Breast Cancer
What this study did
Endometrial Cancer
HR+/HER2- Metastatic Breast Cancer
NCT04595565 · GBG Forschungs GmbH
2020-10-28 – 2029-03-30 · HER2-negative Breast Cancer, Triple Negative Breast Cancer
What this study did
NCT05840211 · Gilead Sciences
2023-05-08 – 2028-04 · Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
What this study did
NCT04639986 · Gilead Sciences
2020-11-23 – 2026-12 · Metastatic Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT06431633 · Fundación GECP
2025-02-04 – 2031-11-30 · Lung Diseases, Carcinoma, Non-Small-Cell Lung, Resectable Lung Non-Small Cell Carcinoma
What this study did
Urothelial Carcinoma
NCT06524544 · National Cancer Institute (NCI)
2025-12-02 – 2030-12-31 · Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
What this study did
Other / comorbidity
NCT06801834 · Gilead Sciences
2025-04-04 – 2029-10 · Extensive Stage Small Cell Lung Cancer (ES-SCLC)
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT06243393 · University Hospital Heidelberg
2024-04-19 – 2029-02-01 · Metastatic Colorectal Cancer
What this study did
Phase 2 (76)
Breast Cancer
NCT07271992 · First Hospital of China Medical University
2025-12-15 – 2031-12-14 · TNBC, Triple Negative Breast Cancer
What this study did
NCT05332561 · German Cancer Research Center
2023-06-29 – 2030-12 · Early-stage Breast Cancer
What this study did
NCT07947823 · Massachusetts General Hospital
2027-04-21 – 2030-09-01 · Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer
What this study did
NCT04230109 · Massachusetts General Hospital
2020-07-14 – 2029-10 · Invasive Breast Cancer, Triple Negative Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, HER2-negative Breast Cancer
What this study did
NCT07151586 · UNICANCER
2026-09 – 2029-10 · Triple Negative Breast Neoplasms, Neoplasm Metastasis, HER 2 Low-expressing Breast Cancer
What this study did
NCT04468061 · Dana-Farber Cancer Institute
2020-07-20 – 2029-04-01 · Breast Cancer, Triple Negative Breast Cancer, PD-L1 Negative
What this study did
NCT07134556 · MedSIR
2026-04 – 2028-12-28 · Triple Negative Breast Cancer, PDL-1 Positive
What this study did
NCT07299409 · Nathalie Levasseur
2026-01-20 – 2028-03 · Advanced Triple Negative Breast Cancer, Breast Cancer Metastatic, Breast Cancer
What this study did
NCT06616987 · Yeon Hee Park
2025-07-03 – 2027-12-31 · Breast Cancer Metastatic
What this study did
NCT04434040 · Dana-Farber Cancer Institute
2020-07-02 – 2027-12-30 · Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNA
What this study did
NCT04454437 · Gilead Sciences
2020-10-23 – 2027-12 · Metastatic Triple-negative Breast Cancer
What this study did
NCT06100874 · Adrienne G. Waks
2023-11-20 – 2027-11-30 · Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic
What this study did
NCT06878625 · Tianjin Medical University Cancer Institute and Hospital
2024-12-06 – 2027-06-30 · Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer
What this study did
NCT03971409 · Laura Huppert, MD, BA
2019-07-08 – 2027-01-31 · Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma
What this study did
NCT07359404 · YING FAN
2024-04-01 – 2026-12-31 · Advanced Breast Cancer
What this study did
NCT05675579 · M.D. Anderson Cancer Center
2023-05-23 – 2026-12-31 · Breast Cancer
What this study did
NCT03606967 · National Cancer Institute (NCI)
2021-04-13 – 2026-12-30 · Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
What this study did
NCT05520723 · MedSIR
2023-02-06 – 2025-11-05 · Triple Negative Breast Cancer, Breast Cancer, Advanced HR+/HER2- Breast Cancer
What this study did
NCT04958785 · Gilead Sciences
2021-12-14 – 2024-10-08 · Triple-Negative Breast Cancer
What this study did
NCT05113966 · G1 Therapeutics, Inc.
2021-12-08 – 2024-06-13 · Triple Negative Breast Cancer
What this study did
NCT05008510 · Veru Inc.
2021-12-30 – 2023-06-30 · Metastatic Triple Negative Breast Cancer
What this study did
NCT02161679 · Gilead Sciences
2016-08 – 2016-08 · Triple-negative Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT04986579 · Dana-Farber Cancer Institute
2021-10-07 – 2030-06-01 · Metastatic Breast Cancer, Chemotherapy-induced Alopecia
What this study did
NCT07825753 · Fudan University
2026-09-10 – 2030-02-01 · Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC)
What this study did
NCT07471776 · Fudan University
2026-03-11 – 2029-03-11 · Metastatic Breast Cancer ( HER2 Negative)
What this study did
NCT06665178 · British Columbia Cancer Agency
2025-03-31 – 2028-12-01 · Breast Cancer
What this study did
NCT07368543 · Fudan University
2026-01-16 – 2028-12-01 · Metastatic Breast Cancer
What this study did
NCT04647916 · SWOG Cancer Research Network
2021-06-08 – 2028-12 · Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT06263543 · Reshma L. Mahtani, D.O.
2024-06-17 – 2028-12 · Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Low Breast Cancer
What this study did
NCT05601440 · Canadian Cancer Trials Group
2023-06-13 – 2028-06-30 · Breast Cancer
What this study did
NCT07367178 · MedSIR
2026-07 – 2028-01 · Breast Cancer, Advanced HR+/HER2- Breast Cancer, Advanced Triple-Negative Breast Cancer
What this study did
NCT06462079 · Guangzhou Medical University
2024-06-15 – 2027-07-15 · Brain Metastasis
What this study did
NCT04448886 · Ana C Garrido-Castro, MD
2020-09-23 – 2027-06-01 · Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer, HER2-negative Breast Cancer
What this study did
NCT06409390 · H. Lee Moffitt Cancer Center and Research Institute
2024-08-14 – 2027-04 · Metastatic Breast Cancer
What this study did
NCT06236269 · SOLTI Breast Cancer Research Group
2024-03-15 – 2027-02-20 · Breast Cancer Stage IV
What this study did
Non-Small Cell Lung Cancer
NCT06055465 · Chinese University of Hong Kong
2024-02-28 – 2029-12-30 · Lung Cancer
What this study did
NCT07393555 · SWOG Cancer Research Network
2026-09-22 – 2029-11 · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT05633667 · Gilead Sciences
2023-03-16 – 2029-09 · Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
What this study did
NCT06667167 · Nir Peled
2024-12-24 – 2028-11-01 · NSCLC (non-small Cell Lung Cancer)
What this study did
NCT07438600 · Tianjin Medical University Cancer Institute and Hospital
2026-02-24 – 2028-02-28 · NSCLC (Non-small Cell Lung Cancer)
What this study did
NCT06401824 · Maastricht University Medical Center
2025-04-24 – 2027-04-01 · NSCLC Stage IV, Brain Metastases, Adult
What this study did
NCT05186974 · Gilead Sciences
2022-05-30 – 2027-03 · Non-small Cell Lung Cancer
What this study did
Urothelial Carcinoma
NCT03547973 · Gilead Sciences
2018-08-13 – 2030-04 · Metastatic Urothelial Cancer
What this study did
NCT06528483 · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
2024-12-02 – 2029-12-31 · Bladder Cancer, Bladder Urothelial Carcinoma, Bladder Neoplasm, Muscle-Invasive Bladder Carcinoma
What this study did
NCT05535218 · Claudia Guerrieri
2023-09-20 – 2027-02 · Muscle-invasive Urothelial Carcinoma of the Bladder
What this study did
NCT05327530 · EMD Serono Research & Development Institute, Inc.
2022-08-17 – 2027-01-22 · Locally Advanced or Metastatic Urothelial Carcinoma
What this study did
NCT06682728 · University of California, Irvine
2024-11-15 – 2026-12-01 · Urothelial Carcinoma, Muscle-invasive Bladder Cancer
What this study did
NCT05226117 · IRCCS San Raffaele
2022-03-23 – 2025-09-24 · Urothelial Carcinoma
What this study did
Other / comorbidity
NCT07492914 · West China Hospital
2026-05-11 – 2031-03-31 · Resectable Head and Neck Squamous Cell Carcinoma
What this study did
NCT06133517 · Fundación para el Progreso de la Oncología en Cantabria
2025-01-20 – 2030-12 · Urothelial Bladder Carcinoma
What this study did
Phase 1/2 (24)
Breast Cancer
NCT06963905 · Yale University
2025-12-29 – 2030-12 · Metastatic Triple-negative Breast Cancer
What this study did
NCT07011654 · M.D. Anderson Cancer Center
2025-09-19 – 2030-07-01 · Metastatic Triple-Negative Breast Cancer
What this study did
NCT06926920 · Gilead Sciences
2025-04-30 – 2028-06 · Triple Negative Breast Cancer
What this study did
NCT06238921 · H. Lee Moffitt Cancer Center and Research Institute
2024-12-19 – 2027-02 · Breast Cancer, Triple Negative Breast Cancer
What this study did
NCT04927884 · ImmunityBio, Inc.
2021-09-08 – 2022-12-12 · Advanced Triple Negative Breast Cancer
What this study did
Endometrial Cancer
NCT06040970 · Icahn School of Medicine at Mount Sinai
2024-10-28 – 2032-07-01 · Ovarian Cancer, Malignant Neoplasm of Uterus
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT03424005 · Hoffmann-La Roche
2018-03-30 – 2030-09-30 · Metastatic Breast Cancer
What this study did
NCT05867251 · Avenzo Therapeutics, Inc.
2023-08-30 – 2030-01-31 · Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, TNBC - Triple-Negative Breast Cancer
What this study did
NCT04039230 · Massachusetts General Hospital
2019-10-09 – 2029-01 · Breast Cancer
What this study did
NCT06827613 · Marengo Therapeutics, Inc.
2025-03-24 – 2028-01 · Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer
What this study did
NCT06612203 · MedSIR
2025-01-17 – 2027-10 · Advanced Breast Cancer
What this study did
NCT06462092 · Guangzhou Medical University
2026-01-01 – 2027-06-15 · Leptomeningeal Metastases
What this study did
NCT05101096 · Gilead Sciences
2021-10-20 – 2027-05 · Advanced Solid Tumor, Metastatic Triple-Negative Breast Cancer, HR+/HER2- Metastatic Breast Cancer, Metastatic Urothelial Cancer
What this study did
NCT06328387 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2024-01-29 – 2026-03-01 · Advanced Breast Cancer, Metastatic Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT03337698 · Hoffmann-La Roche
2017-12-27 – 2025-11-25 · Carcinoma, Non-Small-Cell Lung
What this study did
Urothelial Carcinoma
NCT04724018 · Dana-Farber Cancer Institute
2021-05-20 – 2028-05-01 · Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Bladder Cancer
What this study did
NCT04863885 · H. Lee Moffitt Cancer Center and Research Institute
2021-04-30 – 2027-10 · Metastatic Urothelial Carcinoma
What this study did
NCT03869190 · Hoffmann-La Roche
2019-06-01 – 2025-12-22 · Urothelial Carcinoma, Bladder Cancer
What this study did
NCT03992131 · pharmaand GmbH
2019-06-28 – 2022-04-22 · Ovarian Cancer, Triple-negative Breast Cancer, Urothelial Carcinoma, Solid Tumor
What this study did
Other / comorbidity
NCT04826341 · National Cancer Institute (NCI)
2021-09-20 – 2026-07-01 · HRD Cancer, SCLC, Advanced Solid Tumors
What this study did
NCT07328490 · National Cancer Institute (NCI)
2026-04-25 – 2026-04-25 · Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Small Cell Carcinoma
What this study did
NCT06123468 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2024-04-17 – 2026-01-07 · Esophagogastric Adenocarcinoma
What this study did
NCT04143711 · Dragonfly Therapeutics
2019-11-11 – 2025-12-05 · Solid Tumor, Adult
What this study did
Phase 1 (10)
HR+/HER2- Metastatic Breast Cancer
NCT07163481 · Hunan Cancer Hospital
2025-10 – 2026-12 · Stage IV (Metastatic) Breast Cancer
What this study did
NCT05143229 · University of Kansas Medical Center
2022-03-28 – 2026-12 · Breast Cancer
What this study did
Urothelial Carcinoma
NCT05833867 · Shilpa Gupta, MD
2024-04-01 – 2027-10 · Localized Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma
What this study did
Other / comorbidity
NCT06167317 · Gilead Sciences
2024-01-09 – 2028-09 · Advanced Solid Tumors
What this study did
NCT07674615 · Shanghai Gynecologic Oncology Group
2026-09-02 – 2027-06-30 · Epithelial Ovarian Cancer, Fallopian Tube Cancers, Primary, Primary Peritoneal Carcinoma
What this study did
NCT06065371 · Henry Ford Health System
2024-11-20 – 2027-05 · Gastrointestinal Cancer
What this study did
NCT04794699 · IDEAYA Biosciences
2021-04-14 – 2027-02-04 · Solid Tumor
What this study did
NCT04617522 · Gilead Sciences
2021-04-06 – 2026-12 · Advanced or Metastatic Solid Tumor, Liver Failure
What this study did
NCT03995706 · The University of Texas Health Science Center at San Antonio
2019-07-17 – 2024-03-20 · Glioblastoma
What this study did
Phase 4 (1)
Other / comorbidity
NCT04319198 · Gilead Sciences
2020-08-04 – 2024-10-18 · Metastatic Solid Tumors
What this study did
Early phase / not applicable (1)
Breast Cancer
NCT07046455 · Peking University Cancer Hospital & Institute
2025-03-01 – 2027-09-01 · TNBC - Triple-Negative Breast Cancer
What this study did
Used as active comparator (4)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (3)
Breast Cancer
NCT07533123 · Jiangsu Alphamab Biopharmaceuticals Co., Ltd
2026-03-17 – 2030-03-17 · Triple Negative Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07461454 · MediLink Therapeutics (Suzhou) Co., Ltd.
2026-03-17 – 2028-06-30 · Locally Advanced or Metastatic Breast Cancer
What this study did
Urothelial Carcinoma
NCT04579224 · National Cancer Institute (NCI)
2021-06-28 – 2027-10-29 · Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
What this study did
Phase 2 (1)
HR+/HER2- Metastatic Breast Cancer
NCT06102824 · Guangdong Provincial People's Hospital
2024-10-01 – 2028-06-30 · HER2-negative Breast Cancer, Advanced Breast Cancer
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Other / comorbidity
NCT07778368 · Shanghai East Hospital
2026-09-01 – 2029-08-31 · Oral Squamous Cell Carcinoma (OSCC)
What this study did

Competitive landscape

7 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Sacituzumab Govitecan: this drugPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05089734: EVOKE-01 (NCT05089734), primary endpoint overall survival: sacituzumab govitecan 11.1 months vs docetaxel 9.8 months; not statistically significant missed
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Beruzatatug PelitecanPhase 3Antibody–drug conjugateHER3not yet gradedNo reviewed efficacy summary in this indication
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
DostarlimabPhase 3Monoclonal antibodyPD-1Partial signal
NCT04655976: Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 Months (95% CI 10.6 to 14.2) vs Docetaxel (Arm C) 11.3 Months (95% CI 9.5 to 13.9) missed
EnvafolimabPhase 3Monoclonal antibodyPD-L1Weak signal
NCT05068427: Primary endpoint ORR 6.7% (2/30); DCR 50% (15/30); median PFS 3.5 months
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signal
NCT05865990: LMD cohort primary endpoint met: 3-month OS rate 65% (Kaplan-Meier estimate 69.6%, 95% CI 52.0-93.2, P < 0.001)
PF-08634404Phase 3Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05870319: OptiTROP-Lung04 (NCT05870319), primary endpoint median PFS: sacituzumab tirumotecan 8.3 months vs chemotherapy 4.3 months; HR 0.49; p<0.0001
Sotiburafusp AlfaPhase 3Multispecific antibodyPD-L1 / VEGFnot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
UtidelonePhase 3Small moleculeTubulin / microtubulesPartial signal
NCT03693547: Primary endpoint ORR 15.4% (95% CI 4.4%-34.9%) in ITT (N = 26); 19.0% (95% CI 5.4%-41.9%) in per-protocol (N = 21)
BudigalimabPhase 2/3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
ChidamidePhase 2Small moleculeHDACWeak signal
NCT05068427: Objective response rate: 6.7% (2/30); disease control rate 50%; median PFS 3.5 months (95% CI 1.9-5.5). Trial stopped early for futility against an expected ORR of 24%. missed
Denosumab (Xgeva)Phase 2Monoclonal antibodyRANKLPartial signalFeatured results are non-efficacy only in this race
Disitamab VedotinPhase 2Antibody–drug conjugateHER2Weak signalNo reviewed efficacy summary in this indication
Erdafitinib (Balversa)Phase 2Small moleculeFGFR1-4Weak signal
NCT02699606: NSCLC cohort (n=12): objective response rate 0% (no CR or PR); disease control rate 25.0% (95% CI 5.5-57.2%); 3 patients stable disease, 2 with tumor shrinkage >20%. missed
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
NeratinibPhase 2Small moleculeEGFR/HER2Partial signal
NCT00266877: Objective response rate (primary endpoint): 3% in arm A (prior TKI, EGFR-mutation positive, n=91), 0% in arm B (prior TKI, EGFR wild-type, n=48), 0% in arm C (TKI-naive, n=28); 3 of 4 patients with exon 18 G719X EGFR mutation had a partial response missed
Notiretatug RezetecanPhase 2Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
PrifetrastatPhase 2Small moleculeKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
Rinatabart Sesutecan (Rina-S)Phase 2Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab Drozuntecan
Phase 2(overall)
Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Tizetatug RezetecanPhase 2Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
TucatinibPhase 2Small moleculeHER2not yet gradedNo reviewed efficacy summary in this indication
BL-M02D1Phase 1/2Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
GI-101APhase 1/2Protein / enzyme therapeuticCTLA-4 / IL-2Rβγnot yet gradedNo reviewed efficacy summary in this indication
LCB84
Phase 1/2(overall)
Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Puxitatug SamrotecanPhase 1/2Antibody–drug conjugateB7-H4not yet gradedNo reviewed efficacy summary in this indication
AKY-1189Phase 1RadiopharmaceuticalNectin-4 (PVRL4)not yet gradedNo reviewed efficacy summary in this indication
LY4052031Phase 1Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
MT-302
Phase 1(overall)
Gene therapy / editingTROP2not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 94 furthest-along competitors are listed; 516 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(90 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Sacituzumab Govitecan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (16)
November 2026 (1)
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-11 · NCT06329869 · CT.gov ↗
What to watch
December 2026 (15)
Phase 1HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2026-12 · NCT07163481 · CT.gov ↗
What to watch
Phase 1Gastrointestinal CancerRecruiting
Est. primary completion 2026-12 · NCT06065371 · CT.gov ↗
What to watch
Phase 1Advanced or Metastatic Solid Tumor, Liver FailureRecruiting
Est. primary completion 2026-12 · NCT04617522 · CT.gov ↗
What to watch
Phase 1Urothelial CarcinomaRecruiting
Est. primary completion 2026-12 · NCT05833867 · CT.gov ↗
What to watch
Phase 2Endometrial CarcinomaActive not recruiting
Est. primary completion 2026-12 · NCT04251416 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12 · NCT04639986 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2026-12-01 · NCT06682728 · CT.gov ↗
What to watch
Phase 2Cervical CancerRecruiting
Est. primary completion 2026-12-01 · NCT05838521 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2026-12-30 · NCT04434040 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2026-12-30 · NCT03606967 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaNot yet recruiting
Est. primary completion 2026-12-31 · NCT06528483 · CT.gov ↗
What to watch
Phase 2Solid Tumor, Precision MedicineRecruiting
Est. primary completion 2026-12-31 · NCT06739395 · CT.gov ↗
What to watch
Phase 2Breast CancerEnrolling by invitation
Est. primary completion 2026-12-31 · NCT07359404 · CT.gov ↗
What to watch
Phase 2Resectable Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT07492914 · CT.gov ↗
What to watch
Phase 2Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT05675579 · CT.gov ↗
What to watch
2027 (36)
January 2027 (7)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-01 · NCT06827613 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-01 · NCT04039230 · CT.gov ↗
What to watch
Phase 1Solid TumorActive not recruiting
Est. primary completion 2027-01-07 · NCT04794699 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-01-12 · NCT05609968 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-01-15 · NCT06462092 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-01-15 · NCT06462079 · CT.gov ↗
What to watch
Phase 2Breast CancerActive not recruiting
Est. primary completion 2027-01-31 · NCT03971409 · CT.gov ↗
What to watch
February 2027 (6)
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-02 · NCT06612203 · CT.gov ↗
What to watch
Phase 1/2Breast CancerRecruiting
Est. primary completion 2027-02 · NCT06238921 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaActive not recruiting
Est. primary completion 2027-02 · NCT05535218 · CT.gov ↗
What to watch
Phase 3Breast CancerActive not recruiting
Est. primary completion 2027-02 · NCT05382286 · CT.gov ↗
What to watch
Phase 1/2Urothelial CarcinomaRecruiting
Est. primary completion 2027-02-01 · NCT04724018 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-02-28 · NCT07438600 · CT.gov ↗
What to watch
March 2027 (3)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-03 · NCT05186974 · CT.gov ↗
What to watch
Early phase / not applicableBreast CancerRecruiting
Est. primary completion 2027-03-01 · NCT07046455 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-03-30 · NCT04595565 · CT.gov ↗
What to watch
April 2027 (2)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04 · NCT06409390 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-04-01 · NCT04468061 · CT.gov ↗
What to watch
May 2027 (3)
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-05 · NCT05101096 · CT.gov ↗
What to watch
Phase 2Thymoma, Thymic CarcinomaRecruiting
Est. primary completion 2027-05 · NCT06248515 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-05-01 · NCT06665178 · CT.gov ↗
What to watch
June 2027 (7)
Phase 2Triple Negative Breast NeoplasmsNot yet recruiting
Est. primary completion 2027-06 · NCT07040644 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-06 · NCT07367178 · CT.gov ↗
What to watch
Phase 3Breast CancerRecruiting
Est. primary completion 2027-06 · NCT05633654 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-06-01 · NCT07368543 · CT.gov ↗
What to watch
Phase 1Epithelial Ovarian Cancer, Fallopian Tube Cancers, Primary, Primary Peritoneal CarcinomaRecruiting
Est. primary completion 2027-06-30 · NCT07674615 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-06-30 · NCT06878625 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-06-30 · NCT06616987 · CT.gov ↗
What to watch
August 2027 (2)
Phase 2Breast CancerRecruiting
Est. primary completion 2027-08 · NCT07299409 · CT.gov ↗
What to watch
Phase 2Recurrent GlioblastomaRecruiting
Est. primary completion 2027-08 · NCT04559230 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-09-01 · NCT07825753 · CT.gov ↗
What to watch
November 2027 (2)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-11-01 · NCT06667167 · CT.gov ↗
What to watch
Phase 2Small Cell Carcinoma of the Bladder, Small Cell Carcinoma of the Urinary Tract, Squamous Cell Carcinoma of the Bladder …Recruiting
Est. primary completion 2027-11-01 · NCT06161532 · CT.gov ↗
What to watch
December 2027 (3)
Phase 2Differentiated Thyroid Cancer, Anaplastic Thyroid CancerRecruiting
Est. primary completion 2027-12 · NCT06235216 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT04647916 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05601440 · CT.gov ↗
What to watch
2028 (19)
January 2028 (2)
Phase 2Squamous Cell Carcinoma of Head and Neck, Sinus Cancer, Nasal Cavity Cancer, Oral Cavity Cancer, Oropharynx Cancer, Hypopharynx Cancer …Recruiting
Est. primary completion 2028-01-02 · NCT07063212 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-01-31 · NCT05867251 · CT.gov ↗
What to watch
March 2028 (2)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-03-11 · NCT07471776 · CT.gov ↗
What to watch
Phase 2Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid NeoplasmRecruiting
Est. primary completion 2028-03-31 · NCT06311214 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2028-04 · NCT05840211 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2Triple Negative Breast NeoplasmsNot yet recruiting
Est. primary completion 2028-05-31 · NCT07788222 · CT.gov ↗
What to watch
June 2028 (3)
Phase 1/2Breast CancerRecruiting
Est. primary completion 2028-06 · NCT06926920 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-06 · NCT06263543 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-06-01 · NCT04986579 · CT.gov ↗
What to watch
July 2028 (3)
Phase 3Breast CancerActive not recruiting
Est. primary completion 2028-07 · NCT05382299 · CT.gov ↗
What to watch
Phase 1/2Breast CancerRecruiting
Est. primary completion 2028-07-01 · NCT07011654 · CT.gov ↗
What to watch
Phase 2Gland, Salivary Gland CancersActive not recruiting
Est. primary completion 2028-07-31 · NCT05884320 · CT.gov ↗
What to watch
August 2028 (2)
Phase 2Metastatic HER2-Negative Breast Carcinoma, Metastatic Triple-Negative Breast CarcinomaRecruiting
Est. primary completion 2028-08-01 · NCT05770531 · CT.gov ↗
What to watch
Phase 2/3Metastatic Colorectal CancerRecruiting
Est. primary completion 2028-08-01 · NCT06243393 · CT.gov ↗
What to watch
September 2028 (2)
Phase 1Advanced Solid TumorsRecruiting
Est. primary completion 2028-09 · NCT06167317 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-09-01 · NCT07947823 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2028-10 · NCT04230109 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-11-30 · NCT07393555 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-12-30 · NCT06055465 · CT.gov ↗
What to watch
2029 (8)
February 2029 (1)
Phase 2Small Cell Lung Cancer ( SCLC ), Extensive Stage Small Cell Lung Cancer (ES-SCLC)Recruiting
Est. primary completion 2029-02-01 · NCT07339059 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma …Recruiting
Est. primary completion 2029-04-12 · NCT07504588 · CT.gov ↗
What to watch
June 2029 (2)
Phase 3Endometrial CancerActive not recruiting
Est. primary completion 2029-06 · NCT06486441 · CT.gov ↗
What to watch
Phase 2Mesothelioma, Mesotheliomas Pleural, Mesothelioma; PleuraRecruiting
Est. primary completion 2029-06-21 · NCT06477419 · CT.gov ↗
What to watch
September 2029 (2)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-09 · NCT05633667 · CT.gov ↗
What to watch
Phase 3Breast CancerRecruiting
Est. primary completion 2029-09 · NCT06081244 · CT.gov ↗
What to watch
October 2029 (2)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2029-10 · NCT07151586 · CT.gov ↗
What to watch
Phase 3Extensive Stage Small Cell Lung Cancer (ES-SCLC)Recruiting
Est. primary completion 2029-10 · NCT06801834 · CT.gov ↗
What to watch
2030 (8)
January 2030 (1)
Phase 2Urothelial Bladder CarcinomaActive not recruiting
Est. primary completion 2030-01 · NCT06133517 · CT.gov ↗
What to watch
March 2030 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2030-03 · NCT05332561 · CT.gov ↗
What to watch
April 2030 (2)
Phase 2Salivary Gland Cancer, Thyroid CancerRecruiting
Est. primary completion 2030-04 · NCT06923826 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaActive not recruiting
Est. primary completion 2030-04 · NCT03547973 · CT.gov ↗
What to watch
September 2030 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗
What to watch
December 2030 (3)
Phase 1/2Breast CancerRecruiting
Est. primary completion 2030-12 · NCT06963905 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2030-12-14 · NCT07271992 · CT.gov ↗
What to watch
Phase 3Urothelial CarcinomaRecruiting
Est. primary completion 2030-12-31 · NCT06524544 · CT.gov ↗
What to watch
2031 (2)
July 2031 (1)
Phase 1/2Endometrial CancerRecruiting
Est. primary completion 2031-07-01 · NCT06040970 · CT.gov ↗
What to watch
November 2031 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2031-11-30 · NCT06431633 · CT.gov ↗
What to watch
2033 (1)
March 2033 (1)
Phase 3Breast CancerNot yet recruiting
Est. primary completion 2033-03-31 · NCT07178730 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 June 2026Topline resultKEYNOTE-D46/EVOKE-03 (NCT05609968) Phase 3 discontinued: PFS primary endpoint not statistically significant
Merck and Gilead Sciences · Source ↗
October 2024WithdrawalGilead withdraws the US accelerated approval of Trodelvy in metastatic urothelial cancer
US, FDA · Gilead Sciences · Source ↗